Anhengji (recombinant human coagulation factor VIII biosimilar) / Alphamab, Sino Biopharm - LARVOL DELTA

A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A (clinicaltrials.gov) - P3 | N=60 | Active, not recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Apr 2025 ➔ Jul 2026 | Trial primary completion date: Apr 2025 ➔ Jul 2026

Enrollment closed • Trial completion date • Trial primary completion date • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases